We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.41%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$67.1B
AUM Growth
-$1.4B
(-2%)
Cap. Flow
+$2.19B
Cap. Flow
% of AUM
3.26%
Top 10 Holdings %
Top 10 Hldgs %
22.03%
Holding
3,122
New
29
Increased
2,768
Reduced
217
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$146M |
| 2 |
Apple
AAPL
|
+$75.7M |
| 3 |
Tesla
TSLA
|
+$70.4M |
| 4 |
Amazon
AMZN
|
+$65M |
| 5 |
Procter & Gamble
PG
|
+$55.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACC
American Campus Communities, Inc.
ACC
|
+$27.2M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$21.1M |
| 3 |
CDK
CDK Global, Inc.
CDK
|
+$19.2M |
| 4 |
COHR
Coherent Inc
COHR
|
+$18.8M |
| 5 |
SAIL
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
|
+$18.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 14.42% |
| 3 | Financials | 13.62% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KLRS
2626
Kalaris Therapeutics
KLRS
$96.8M
| $376K | ﹤0.01% |
2,074
+186
| +10% | +$29K |
|
|
GBIO
2627
DELISTED
Generation Bio
GBIO
| $375K | ﹤0.01% |
7,066
+588
| +9% | +$36.8K |
|
2628
Vera Therapeutics
VERA
$2.36B
| $375K | ﹤0.01% |
17,600
+1,328
| +8% | +$24.9K |
|
2629
Hippo Holdings
HIPO
$861M
| $374K | ﹤0.01% |
20,179
+5,746
| +40% | +$127K |
|
2630
Orrstown Financial Services
ORRF
$838M
| $374K | ﹤0.01% |
15,626
+862
| +6% | +$22K |
|
2631
Utah Medical Products
UTMD
$225M
| $374K | ﹤0.01% |
4,389
+275
| +7% | +$24.3K |
|
|
WE
2632
DELISTED
WeWork Inc.
WE
| $372K | ﹤0.01% |
3,506
+880
| +34% | +$158K |
|
|
AFCG
2633
AFC Gamma
AFCG
$63.4M
| $370K | ﹤0.01% |
35,292
+2,016
| +6% | +$23.3K |
|
|
MCBC
2634
DELISTED
Macatawa Bank Corp
MCBC
| $370K | ﹤0.01% |
40,006
+2,318
| +6% | +$21.8K |
|
2635
ACNB Corp
ACNB
$655M
| $367K | ﹤0.01% |
12,232
+676
| +6% | +$22.5K |
|
2636
Atlanta Braves Holdings Series A
BATRA
$3.43B
| $366K | ﹤0.01% |
13,016
+856
| +7% | +$24.2K |
|
2637
4D Molecular Therapeutics
FDMT
$562M
| $365K | ﹤0.01% |
45,373
+3,788
| +9% | +$34.3K |
|
2638
Quantum-Si Incorporated
QSI
$177M
| $365K | ﹤0.01% |
132,596
+7,503
| +6% | +$24K |
|
2639
Hyster-Yale Materials Handling
HY
$665M
| $364K | ﹤0.01% |
16,931
+967
| +6% | +$30.1K |
|
|
ATH.PRA
2640
Athene Holding Ltd Series A
ATH.PRA
$825M
| $363K | ﹤0.01% |
14,875
| – | – |
|
2641
Liberty Latin America Class A
LILA
$1.67B
| $363K | ﹤0.01% |
86,403
+5,765
| +7% | +$27.8K |
|
2642
PLAYSTUDIOS Inc
MYPS
$90.1M
| $363K | ﹤0.01% |
103,957
+6,403
| +7% | +$24.4K |
|
2643
Lifecore Biomedical
LFCR
$190M
| $362K | ﹤0.01% |
40,701
+2,820
| +7% | +$28.7K |
|
2644
BCB Bancorp
BCBP
$161M
| $360K | ﹤0.01% |
21,408
+1,096
| +5% | +$20.2K |
|
2645
BioXcel Therapeutics
BTAI
$27.8M
| $359K | ﹤0.01% |
1,897
+115
| +6% | +$26.7K |
|
2646
Rackspace Technology
RXT
$1.24B
| $359K | ﹤0.01% |
87,977
+5,674
| +7% | +$32.9K |
|
|
AFMD
2647
DELISTED
Affimed
AFMD
| $358K | ﹤0.01% |
17,396
+949
| +6% | +$26.4K |
|
2648
Northeast Bank
NBN
$1.14B
| $357K | ﹤0.01% |
9,734
+543
| +6% | +$21.3K |
|
2649
Upland Software
UPLD
$15.4M
| $357K | ﹤0.01% |
4,388
+241
| +6% | +$26.7K |
|
|
TPC
2650
Tutor Perini Cor
TPC
$5.21B
| $356K | ﹤0.01% |
64,513
+4,042
| +7% | +$30.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2022 Portfolio in Review
As of Q3 2022, RhumbLine Advisers held 3,122 positions worth $67.1B, down 2% from $68.5B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers deployed $2.19B of net new capital in Q3 2022, opening 29 new positions and adding to 2,768 existing holdings. Its largest new stake was Enhabit: 136,327 shares worth $1.91M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $21.1M trimmed.
- RhumbLine Advisers's largest Q3 2022 buy was Enhabit: 136,327 shares worth $1.91M.
- RhumbLine Advisers added most to Microsoft in Q3 2022, an estimated $146M increase.
- RhumbLine Advisers's biggest Q3 2022 reduction was iShares Core S&P 500 ETF, cutting an estimated $21.1M.
- RhumbLine Advisers fully exited American Campus Communities, Inc. in Q3 2022, selling an estimated $27.2M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $67.1B portfolio in Q3 2022.
- RhumbLine Advisers opened 29 new positions and closed 40 in Q3 2022.
- RhumbLine Advisers's portfolio value fell 2% quarter-over-quarter to $67.1B.
Based on RhumbLine Advisers's 13F filing for Q3 2022, filed 10 Nov 2022.